SHL.DE

50.26

-0.95%↓

ARGX

488.1

+0.16%↑

VIE

29.64

-1%↓

BNR

64.2

-2.1%↓

GLPG

24.94

-1.97%↓

SHL.DE

50.26

-0.95%↓

ARGX

488.1

+0.16%↑

VIE

29.64

-1%↓

BNR

64.2

-2.1%↓

GLPG

24.94

-1.97%↓

SHL.DE

50.26

-0.95%↓

ARGX

488.1

+0.16%↑

VIE

29.64

-1%↓

BNR

64.2

-2.1%↓

GLPG

24.94

-1.97%↓

SHL.DE

50.26

-0.95%↓

ARGX

488.1

+0.16%↑

VIE

29.64

-1%↓

BNR

64.2

-2.1%↓

GLPG

24.94

-1.97%↓

SHL.DE

50.26

-0.95%↓

ARGX

488.1

+0.16%↑

VIE

29.64

-1%↓

BNR

64.2

-2.1%↓

GLPG

24.94

-1.97%↓

Search

Sanofi SA

Geschlossen

Branche Gesundheitswesen

104.78 -0.46

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

104.78

Max

105.34

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.1B

Verkäufe

916M

11B

KGV

Branchendurchschnitt

24.91

103.001

EPS

1.73

Gewinnspanne

9.78

EBITDA

-136M

2B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+3.32 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

25. Okt. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

131B

Vorheriger Eröffnungskurs

105.24

Vorheriger Schlusskurs

104.78

Nachrichtenstimmung

By Acuity

50%

50%

114 / 365 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Sanofi SA Chart

Ähnliche Nachrichten

25. Juli 2024, 05:44 UTC

Ergebnisse

Sanofi Raises Guidance After Profit, Sales Beat

24. Juli 2024, 10:24 UTC

Ergebnisse

Spanish Bank Santander Raises 2024 Guidance After Earnings Beat -- Update

24. Juli 2024, 05:22 UTC

Ergebnisse

Santander Raises 2024 Revenue Guidance After Earnings Increase

4. Juli 2024, 06:44 UTC

Akquisitionen, Fusionen, Übernahmen

Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports

27. Juni 2024, 10:54 UTC

Wichtige Markttreiber

Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment

15. Aug. 2024, 08:21 UTC

Market Talk
Ergebnisse

European Banks' Net Interest Income Momentum May Have Stalled -- Market Talk

14. Aug. 2024, 07:07 UTC

Market Talk

Southern European Banks Have Attractive Net Interest Income Dynamics -- Market Talk

26. Juli 2024, 12:53 UTC

Market Talk
Ergebnisse

European Banks' Earnings Season Had Another Good Start -- Market Talk

25. Juli 2024, 13:20 UTC

Ergebnisse

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

25. Juli 2024, 11:46 UTC

Market Talk
Ergebnisse

Sanofi Aims to Boost RSV Drug Supply -- Market Talk

25. Juli 2024, 11:23 UTC

Market Talk
Ergebnisse

Sanofi Results Are Positive -- Market Talk

25. Juli 2024, 05:33 UTC

Ergebnisse

Analysts Saw Sanofi 2Q Sales at EUR10.4B

25. Juli 2024, 05:33 UTC

Ergebnisse

Sanofi 2Q Sales EUR10.745B

25. Juli 2024, 05:30 UTC

Ergebnisse

Sanofi Had Seen 2024 Business Earnings Per Share Decreasing Low Single Digit at Constant Currency

25. Juli 2024, 05:30 UTC

Ergebnisse

Sanofi Now Expects 2024 Business Earnings Per Share to Be Stable at Constant Currency

25. Juli 2024, 05:30 UTC

Ergebnisse

Analysts Saw Sanofi 2Q Business Operating Income at EUR2.69B

25. Juli 2024, 05:30 UTC

Ergebnisse

Sanofi 2Q Net Pft EUR1.11B

25. Juli 2024, 05:30 UTC

Ergebnisse

Sanofi Raises 2024 View

25. Juli 2024, 05:30 UTC

Ergebnisse

Sanofi 2Q Business Operating Income EUR2.81B

24. Juli 2024, 06:53 UTC

Market Talk
Ergebnisse

Santander's Small Beats, Improved Outlook Should Be Well Received -- Market Talk

24. Juli 2024, 04:50 UTC

Ergebnisse

Santander Raises 2024 Rev View

24. Juli 2024, 04:50 UTC

Ergebnisse

Santander Fully-Loaded CET1 Ratio 12.5% at 2Q-End

24. Juli 2024, 04:48 UTC

Ergebnisse

Santander 2Q Net Interest Income Fell 4.2%

24. Juli 2024, 04:48 UTC

Ergebnisse

Santander 2Q Net Interest Income EUR11.47B

24. Juli 2024, 04:48 UTC

Ergebnisse

Santander 2Q Net Pft EUR3.21B

24. Juli 2024, 04:47 UTC

Ergebnisse

Santander 2Q Rev EUR15.67B

9. Juli 2024, 09:05 UTC

Top News

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

3. Juli 2024, 14:18 UTC

Akquisitionen, Fusionen, Übernahmen

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

27. Juni 2024, 10:39 UTC

Wichtige Markttreiber

Vigil Neuroscience Shares Soar on $40M Sanofi Investment

27. Juni 2024, 06:08 UTC

Akquisitionen, Fusionen, Übernahmen

Vigil Neuroscience Is a Clinical-Stage Biotechnology Company >VIGL

Peer-Vergleich

Kursveränderung

Sanofi SA Prognose

Kursziel

By TipRanks

3.32% Vorteil

12-Monats-Prognose

Durchschnitt 108.4 EUR  3.32%

Hoch 125 EUR

Tief 85 EUR

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sanofi SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

8

Buy

3

Halten

1

Sell

Technischer Score

By Trading Central

104.9 / 105.78Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

114 / 365 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

$

Über Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.